Literature DB >> 9401762

Quantification and distribution of alpha 1-adrenoceptor subtype mRNAs in human vas deferens: comparison with those of epididymal and pelvic portions.

N Moriyama1, K Nasu, T Takeuchi, K Akiyama, S Murata, H Nishimatsu, J Yano, G Tsujimoto, K Kawabe.   

Abstract

1. This study was intended to quantify the amounts of the alpha 1-adrenoceptor subtype mRNAs in human vas deferens, and demonstrate the receptor subtype responsible for the vas contraction. 2. The RNase protection assay showed that the mean total amount of alpha 1a mRNA was 7.4 +/- 2.2 pg/5 micrograms of poly (A)+ RNA (97.0% of the total alpha 1 mRNA) in the epididymal portion (E-vas) and 4.9 +/- 0.8 pg/5 micrograms of poly (A)+ RNA (96.3% of the total) in the pelvic portion (P-vas). The E-vas showed a tendency to have a greater alpha 1a mRNA abundance than the P-vas (P = 0.11). The alpha 1b and alpha 1d mRNAs were absent or of extremely low abundance. 3. By an in situ hybridization, the alpha 1a and alpha 1d mRNAs were recognized in the smooth muscle cells of the E-vas and the P-vas, and the distribution pattern the same in both tissue. The alpha 1b mRNA positive site was scarcely detectable in both vas portions. 4. In a functional study, l-phenylephrine produced concentration-dependent contraction in the E-vas (Emax = 2.24 +/- 0.70 g; pD2 = 5.32 +/- 0.09) and the P-vas (Emax = 2.46 +/- 0.46 g; pD2 = 5.07 +/- 0.12). KMD-3213, a novel alpha 1A-adrenoceptor-selective antagonist, caused parallel rightward shifts of the concentration-response curves for l-phenylephrine. Apparent pKB values were 9.90 +/- 0.16 for the E-vas and 9.71 +/- 0.17 for the P-vas. There was no significant difference in Emax, pD2 or pKB estimates between the two portions. 5. We have found that alpha 1a mRNA is predominant in the human vas deferens, and confirmed that contraction of this organ is mediated by the alpha 1A-adrenoceptor.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9401762      PMCID: PMC1565044          DOI: 10.1038/sj.bjp.0701485

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  12 in total

1.  Discrimination by SZL49 between contractions evoked by noradrenaline in longitudinal and circular muscle of human vas deferens.

Authors:  Nnaemeka I B Amobi; John Guillebaud; A V Kaisary; Eileen Turner; I Christopher H Smith
Journal:  Br J Pharmacol       Date:  2002-05       Impact factor: 8.739

Review 2.  Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations.

Authors:  Anja Cerovecki; Richard Musil; Ansgar Klimke; Florian Seemüller; Ekkehard Haen; Rebecca Schennach; Kai-Uwe Kühn; Hans-Peter Volz; Michael Riedel
Journal:  CNS Drugs       Date:  2013-07       Impact factor: 5.749

Review 3.  Subtypes of functional alpha1-adrenoceptor.

Authors:  James R Docherty
Journal:  Cell Mol Life Sci       Date:  2009-10-28       Impact factor: 9.261

Review 4.  Impact of alpha blockers, 5-alpha reductase inhibitors and combination therapy on sexual function.

Authors:  Charles Welliver; Michael Butcher; Yogitha Potini; Kevin T McVary
Journal:  Curr Urol Rep       Date:  2014-10       Impact factor: 3.092

Review 5.  Silodosin is effective for treatment of LUTS in men with BPH: a systematic review.

Authors:  Hui Ding; Wan Du; Zi-Zhen Hou; Han-Zhang Wang; Zhi-Ping Wang
Journal:  Asian J Androl       Date:  2012-12-10       Impact factor: 3.285

Review 6.  Silodosin in the treatment of benign prostatic hyperplasia.

Authors:  Maxime Rossi; Thierry Roumeguère
Journal:  Drug Des Devel Ther       Date:  2010-10-27       Impact factor: 4.162

7.  Correlation between lower urinary tract symptoms and premature ejaculation in Korean men older than 40 years old [corrected].

Authors:  Jae Doo Um; Dong Il Kang; Jang Ho Yoon; Kweon Sik Min
Journal:  Korean J Urol       Date:  2012-03-19

8.  Investigation of ejaculatory disorder by silodosin in the treatment of prostatic hyperplasia.

Authors:  Koichi Sakata; Tatsuo Morita
Journal:  BMC Urol       Date:  2012-10-19       Impact factor: 2.264

9.  Efficacy of alfuzosin after shock wave lithotripsy for the treatment of ureteral calculi.

Authors:  Hee Ju Cho; Soon Cheol Shin; Do Young Seo; Dong Suk Min; Jeong Man Cho; Jung Yoon Kang; Tag Keun Yoo
Journal:  Korean J Urol       Date:  2013-02-18

10.  Physiological and pharmacological aspects of the vas deferens-an update.

Authors:  David S Koslov; Karl-Erik Andersson
Journal:  Front Pharmacol       Date:  2013-08-22       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.